Gap Analysis Cross-country PICO matrix · strategic recommendations
Documents
7
+2 this week
Processed
6
1 awaiting review
Validated
9
evidence units
Avg confidence
0.84
per field
⬆
Drop HTA documents here
IPTs · NICE STAs · G-BA dossiers · PDF
Source Documents
DocumentAgencyIndicationDecisionStatusAction
IPT 043/2024 v.1
Pembrolizumab · NSCLC 1L
🇪🇸 AEMPS
NSCLC stage III/IV PD-L1 CPS ≥ 10Jan 2024Validated
TA 888 v.1
Pembrolizumab · NSCLC 1L
🇬🇧 NICE
NSCLC stage III/IV PD-L1 TPS ≥ 50%Nov 2023Validated
IPT 021/2023 v.1
Nivolumab · NSCLC 2L
🇪🇸 AEMPS
NSCLC post-platinum, PD-L1 ≥ 1%Sep 2023Validated
TA 833 v.1
Nivolumab · NSCLC 2L
🇬🇧 NICE
NSCLC squamous, post-platinumJun 2023Validated
GBA-2024-0128
Pembrolizumab · NSCLC 1L
🇩🇪 G-BA
NSCLC non-squamous, PD-L1 TPS ≥ 50%Mar 2024Draft
IPT 019/2024 v.1
Atezolizumab · NSCLC 1L
🇪🇸 AEMPS
NSCLC non-squamous, no EGFR/ALKFeb 2024Validated
IPT 055/2024 v.1
Durvalumab · NSCLC stage III
🇪🇸 AEMPS
NSCLC unresectable stage III, post-CRTMay 2024Extracting
Evidence units
12
across 3 agencies
Drugs covered
4
PD-1/PD-L1 inhibitors
Cross-agency matches
6
same PICO, 2+ agencies
Gap candidates
4
NICE accepted, not AEMPS
Filter:
Evidence Units12 results
Drug · IndicationAgencyPopulationComparatorPrimary HRStatus
1
Stage
Where are you?
2
Scope
Drug & markets
3
Analysis
PICO comparison
4
Recommendation
Strategic actions
What stage is your asset at?
Your answer shapes the analysis and the strategic recommendations you'll see.
🔬
Phase II → III
Designing the pivotal trial. Which study design satisfies all target markets simultaneously?
HEOR · Clinical Development
🚀
Pre-launch
Deciding launch sequence and market entry. Where does current evidence give you access now?
Market Access · HEOR
📋
Dossier preparation
Building the HTA submission. What precedents have agencies accepted for similar drugs?
Regulatory Affairs · HEOR
↗
New indication
Expanding an approved drug to a new indication. What can be reused vs. what needs new evidence?
Clinical Development · HEOR
📡
Market intelligence
Monitoring competitor decisions and regulatory signals. What are agencies accepting right now?
Market Access · Strategy
1
Drug & Indication
Select drug · indication
2
Target markets
💡 Select the markets you want to compare.
🇪🇸 AEMPS
🇬🇧 NICE
🇩🇪 G-BA
🇫🇷 HAS
◈ JCA 2025
← Back to browser